PL4135652T3 - Kompozycje rezyniferatoksyny - Google Patents
Kompozycje rezyniferatoksynyInfo
- Publication number
- PL4135652T3 PL4135652T3 PL21717110.7T PL21717110T PL4135652T3 PL 4135652 T3 PL4135652 T3 PL 4135652T3 PL 21717110 T PL21717110 T PL 21717110T PL 4135652 T3 PL4135652 T3 PL 4135652T3
- Authority
- PL
- Poland
- Prior art keywords
- resiniferatoxin
- compositions
- resiniferatoxin compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169668 | 2020-04-15 | ||
| PCT/EP2021/059562 WO2021209450A1 (en) | 2020-04-15 | 2021-04-13 | Resiniferatoxin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4135652T3 true PL4135652T3 (pl) | 2025-03-10 |
Family
ID=70289711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21717110.7T PL4135652T3 (pl) | 2020-04-15 | 2021-04-13 | Kompozycje rezyniferatoksyny |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20230051321A1 (pl) |
| EP (2) | EP4487872A3 (pl) |
| JP (1) | JP7817171B2 (pl) |
| KR (1) | KR20230002560A (pl) |
| CN (2) | CN121512944A (pl) |
| AU (1) | AU2021256948B2 (pl) |
| BR (1) | BR112022020862A2 (pl) |
| CA (1) | CA3172784A1 (pl) |
| DK (1) | DK4135652T3 (pl) |
| ES (1) | ES3004508T3 (pl) |
| FI (1) | FI4135652T3 (pl) |
| HR (1) | HRP20250055T1 (pl) |
| HU (1) | HUE069859T2 (pl) |
| IL (1) | IL297063A (pl) |
| LT (1) | LT4135652T (pl) |
| MX (1) | MX2022012920A (pl) |
| PL (1) | PL4135652T3 (pl) |
| PT (1) | PT4135652T (pl) |
| RS (1) | RS66427B1 (pl) |
| SI (1) | SI4135652T1 (pl) |
| WO (1) | WO2021209450A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250228815A1 (en) | 2024-01-15 | 2025-07-17 | Gruenenthal Gmbh | Lyophilized resiniferatoxin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711962D0 (en) * | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20040048910A1 (en) * | 2002-08-22 | 2004-03-11 | Bove Susan Elizabeth | Method of treating osteoarthritis |
| US7943166B2 (en) * | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
| ES2533256T3 (es) * | 2004-12-28 | 2015-04-08 | Mestex Ag | Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor |
| EP3219705B1 (en) * | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| AR075180A1 (es) * | 2009-01-29 | 2011-03-16 | Novartis Ag | Formulaciones orales solidas de una pirido-pirimidinona |
| EP3359178A4 (en) * | 2015-10-06 | 2019-08-28 | Flex Pharma, Inc. | METHODS AND COMPOSITIONS FOR UNWANTED OR INORMAL MUSCLE CONTRACTIONS |
| WO2017087803A1 (en) * | 2015-11-20 | 2017-05-26 | Sorrento Therapeutics, Inc. | Methods for pain treatment using resiniferatoxin |
| US20200222430A1 (en) * | 2016-08-02 | 2020-07-16 | Durect Corporation | Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride |
| JP2018024648A (ja) * | 2016-08-05 | 2018-02-15 | 日本化薬株式会社 | ボルテゾミブを含有する医薬製剤の製造方法 |
| WO2018094262A2 (en) * | 2016-11-18 | 2018-05-24 | Mayo Foundation For Medical Education And Research | Materials and methods for treating regional pain |
| KR20200051771A (ko) * | 2017-09-11 | 2020-05-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | 레시니페라톡신 제형 |
| EP3914595A4 (en) * | 2019-01-22 | 2022-11-09 | Sorrento Therapeutics, Inc. | METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN |
-
2021
- 2021-04-13 PL PL21717110.7T patent/PL4135652T3/pl unknown
- 2021-04-13 DK DK21717110.7T patent/DK4135652T3/da active
- 2021-04-13 CN CN202511607952.4A patent/CN121512944A/zh active Pending
- 2021-04-13 EP EP24215210.6A patent/EP4487872A3/en not_active Withdrawn
- 2021-04-13 HU HUE21717110A patent/HUE069859T2/hu unknown
- 2021-04-13 HR HRP20250055TT patent/HRP20250055T1/hr unknown
- 2021-04-13 SI SI202130263T patent/SI4135652T1/sl unknown
- 2021-04-13 MX MX2022012920A patent/MX2022012920A/es unknown
- 2021-04-13 CN CN202180028634.6A patent/CN115551480B/zh active Active
- 2021-04-13 JP JP2022548441A patent/JP7817171B2/ja active Active
- 2021-04-13 EP EP21717110.7A patent/EP4135652B1/en active Active
- 2021-04-13 CA CA3172784A patent/CA3172784A1/en active Pending
- 2021-04-13 RS RS20250062A patent/RS66427B1/sr unknown
- 2021-04-13 PT PT217171107T patent/PT4135652T/pt unknown
- 2021-04-13 KR KR1020227038425A patent/KR20230002560A/ko active Pending
- 2021-04-13 IL IL297063A patent/IL297063A/en unknown
- 2021-04-13 FI FIEP21717110.7T patent/FI4135652T3/fi active
- 2021-04-13 ES ES21717110T patent/ES3004508T3/es active Active
- 2021-04-13 BR BR112022020862A patent/BR112022020862A2/pt unknown
- 2021-04-13 LT LTEPPCT/EP2021/059562T patent/LT4135652T/lt unknown
- 2021-04-13 WO PCT/EP2021/059562 patent/WO2021209450A1/en not_active Ceased
- 2021-04-13 AU AU2021256948A patent/AU2021256948B2/en active Active
-
2022
- 2022-10-17 US US17/967,507 patent/US20230051321A1/en not_active Abandoned
-
2024
- 2024-07-29 US US18/787,515 patent/US20240382449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RS66427B1 (sr) | 2025-02-28 |
| AU2021256948A1 (en) | 2022-09-01 |
| US20240382449A1 (en) | 2024-11-21 |
| DK4135652T3 (da) | 2025-01-20 |
| WO2021209450A1 (en) | 2021-10-21 |
| LT4135652T (lt) | 2025-02-10 |
| PT4135652T (pt) | 2025-01-16 |
| HUE069859T2 (hu) | 2025-04-28 |
| EP4135652A1 (en) | 2023-02-22 |
| CN115551480B (zh) | 2025-11-18 |
| CN121512944A (zh) | 2026-02-13 |
| EP4487872A3 (en) | 2025-03-26 |
| FI4135652T3 (fi) | 2025-01-21 |
| JP2023522537A (ja) | 2023-05-31 |
| BR112022020862A2 (pt) | 2022-11-29 |
| SI4135652T1 (sl) | 2025-03-31 |
| CN115551480A (zh) | 2022-12-30 |
| CA3172784A1 (en) | 2021-10-21 |
| EP4135652B1 (en) | 2024-12-18 |
| IL297063A (en) | 2022-12-01 |
| ES3004508T3 (en) | 2025-03-12 |
| AU2021256948B2 (en) | 2025-06-19 |
| HRP20250055T1 (hr) | 2025-03-28 |
| KR20230002560A (ko) | 2023-01-05 |
| JP7817171B2 (ja) | 2026-02-18 |
| MX2022012920A (es) | 2022-11-16 |
| US20230051321A1 (en) | 2023-02-16 |
| EP4487872A2 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403158B (en) | Compositions | |
| GB202013432D0 (en) | Compositions | |
| GB202015836D0 (en) | Compositions | |
| GB202105461D0 (en) | Compositions | |
| GB202102704D0 (en) | Compositions | |
| PL4065661T3 (pl) | Kompozycje | |
| HUE069859T2 (hu) | Gyantaiferatoxin készítmények | |
| GB2610026B (en) | Compositions | |
| GB202019952D0 (en) | Novel compositions | |
| GB202017863D0 (en) | Novel compositions | |
| ZA202210764B (en) | Compositions | |
| GB202118081D0 (en) | Compositions | |
| GB202117074D0 (en) | Compositions | |
| GB202116861D0 (en) | Compositions | |
| GB202116386D0 (en) | Compositions | |
| GB202116387D0 (en) | Compositions | |
| GB202116388D0 (en) | Compositions | |
| GB202115617D0 (en) | Compositions | |
| GB202114053D0 (en) | Compositions | |
| GB202111897D0 (en) | Compositions | |
| GB202109945D0 (en) | Compositions | |
| GB202109947D0 (en) | Compositions | |
| GB202109944D0 (en) | Compositions | |
| GB202108656D0 (en) | Compositions | |
| GB202114311D0 (en) | New compositions |